Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 271

1.

Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.

Trivedi MH, Corey-Lisle PK, Guo Z, Lennox RD, Pikalov A, Kim E.

Int Clin Psychopharmacol. 2009 May;24(3):133-8. doi: 10.1097/YIC.0b013e3283277614.

PMID:
19318972
2.

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.

Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN.

CNS Spectr. 2009 Apr;14(4):197-206.

PMID:
19407731
3.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.

Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM.

J Clin Psychopharmacol. 2008 Apr;28(2):156-65. doi: 10.1097/JCP.0b013e31816774f9.

PMID:
18344725
4.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A.

J Clin Psychiatry. 2007 Jun;68(6):843-53.

PMID:
17592907
5.

Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.

Nelson JC, Thase ME, Bellocchio EE, Rollin LM, Eudicone JM, McQuade RD, Marcus RN, Berman RM, Baker RA.

Int Clin Psychopharmacol. 2012 May;27(3):125-33. doi: 10.1097/YIC.0b013e3283502791.

PMID:
22466058
6.

Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.

Wisniewski SR, Chen CC, Kim E, Kan HJ, Guo Z, Carlson BX, Tran QV, Pikalov A.

Pharmacoepidemiol Drug Saf. 2009 Oct;18(10):965-72. doi: 10.1002/pds.1805.

PMID:
19662630
7.

Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.

Steffens DC, Nelson JC, Eudicone JM, Andersson C, Yang H, Tran QV, Forbes RA, Carlson BX, Berman RM.

Int J Geriatr Psychiatry. 2011 Jun;26(6):564-72. doi: 10.1002/gps.2564. Epub 2010 Sep 9.

8.

Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.

Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, Kornstein SG, Ninan PT, Kane CP.

CNS Drugs. 2011 Mar;25(3):227-38. doi: 10.2165/11586460-000000000-00000.

PMID:
21323394
9.

Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.

Nelson JC, Rahman Z, Laubmeier KK, Eudicone JM, McQuade RD, Berman RM, Marcus RN, Baker RA, Sheehan JJ.

CNS Spectr. 2014 Dec;19(6):528-34. doi: 10.1017/S109285291300103X. Epub 2014 Mar 18.

10.

Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.

Lin CH, Lin SH, Jang FL.

J Clin Psychopharmacol. 2011 Oct;31(5):563-8. doi: 10.1097/JCP.0b013e31822bb0db.

PMID:
21869699
11.

Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.

Trivedi MH, Thase ME, Fava M, Nelson CJ, Yang H, Qi Y, Tran QV, Pikalov A, Carlson BX, Marcus RN, Berman RM.

J Clin Psychiatry. 2008 Dec;69(12):1928-36. Epub 2008 Dec 2.

PMID:
19192475
12.

Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.

Weisler RH, Khan A, Trivedi MH, Yang H, Eudicone JM, Pikalov A, Tran QV, Berman RM, Carlson BX.

J Clin Psychiatry. 2011 Apr;72(4):548-55. doi: 10.4088/JCP.09m05495gre. Epub 2010 Aug 24.

PMID:
20816039
13.

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.

El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H.

Int J Neuropsychopharmacol. 2010 Aug;13(7):917-32. doi: 10.1017/S1461145710000015. Epub 2010 Feb 23.

PMID:
20175941
14.
15.

Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.

Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M.

J Clin Psychiatry. 2012 Mar;73(3):353-7. doi: 10.4088/JCP.10m06541. Epub 2011 Sep 20.

PMID:
21939613
16.

[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].

OliƩ JP, Gourion D, Montagne A, Rostin M, Poirier MF.

Encephale. 2009 Dec;35(6):595-604. doi: 10.1016/j.encep.2009.10.011. Epub . French.

PMID:
20004291
17.

Aripiprazole: in major depressive disorder.

Weber J, Lyseng-Williamson KA, Scott LJ.

CNS Drugs. 2008;22(10):807-13. Review.

PMID:
18788833
18.

Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.

Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A.

Int Clin Psychopharmacol. 2012 Jan;27(1):27-39. doi: 10.1097/YIC.0b013e32834d6f91.

PMID:
22027845
19.

A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).

Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M.

Psychother Psychosom. 2012;81(2):87-97. doi: 10.1159/000332050. Epub 2012 Jan 25. Erratum in: Psychother Psychosom. 2012;81(4):261.

PMID:
22286203
20.

Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.

Sheehan DV, Harnett-Sheehan K, Spann ME, Thompson HF, Prakash A.

Int Clin Psychopharmacol. 2011 Mar;26(2):75-83. doi: 10.1097/YIC.0b013e328341bb5f.

PMID:
21102344
Items per page

Supplemental Content

Write to the Help Desk